



(51) International Patent Classification:

C07D 471/04 (2006.01) A61K 31/4985 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/GB2012/052672

(22) International Filing Date:

26 October 2012 (26.10.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1118656.6 28 October 2011 (28.10.2011) GB
61/552,888 28 October 2011 (28.10.2011) US

(71) Applicant: **ASTEX THERAPEUTICS LIMITED**
[GB/GB]; 436 Cambridge Science Park, Milton Road,
Cambridge, Cambridgeshire CB4 0QA (GB).(72) Inventors: **BERDINI, Valerio**; c/o Astex Therapeutics
Limited, 436 Cambridge Science Park, Milton Road, Cam-
bridge, Cambridgeshire CB4 0QA (GB). **SAXTY, Gor-
don**; c/o Astex Therapeutics Limited, 436 Cambridge Sci-
ence Park, Milton Road, Cambridge, Cambridgeshire CB4
0QA (GB). **ANGIBAUD, Patrick René**; c/o Janssen-Cilag
Centre de Recherche, Campus de Maigremont, BP 615, F-
27106 Val de Reuil Cedex (FR). **QUEROLLE, Olivier
Alexis Georges**; c/o Janssen-Cilag Centre de Recherche,
Campus de Maigremont, BP 615, F-27106 Val de Reuil

Cedex (FR). **PONCELET, Virginie Sophie**; c/o Janssen-
Cilag Centre de Recherche, Campus de Maigremont, BP
615, F-27106 Val de Reuil Cedex (FR). **ROUX, Bruno**;
c/o Janssen-Cilag Centre de Recherche, Campus de
Maigremont, BP 615, F-27106 Val de Reuil Cedex (FR).
MEERPOEL, Lieven; c/o Janssen Pharmaceutica NV,
Turnhoutseweg 30, B-2340 Beerse (BE).


(74) Agent: **BARKER BRETTELL LLP**; 100 Hagley Road,
Edgbaston, Birmingham, B16 8QQ (GB).

(81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.


(84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

[Continued on next page]

(54) Title: ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES



or



(57) **Abstract:** The invention relates to new pyridopyrazine derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

— *of inventorship (Rule 4.17(iv))*

Declarations under Rule 4.17:

Published:

— *as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii))*

— *with international search report (Art. 21(3))*

— *as to the applicant's entitlement to claim the priority of
the earlier application (Rule 4.17(iii))*